CureVac Can Finally Compete With Moderna. It’s an ‘Under-the-Radar mRNA Story.’
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.